Edition:
India

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

2.71USD
8:52pm IST
Change (% chg)

$0.01 (+0.37%)
Prev Close
$2.70
Open
$2.72
Day's High
$2.78
Day's Low
$2.71
Volume
2,070
Avg. Vol
143,559
52-wk High
$11.90
52-wk Low
$2.33

Latest Key Developments (Source: Significant Developments)

Capricor Therapeutics Posts Q2 Loss Per Share Of $0.59
Wednesday, 7 Aug 2019 

Aug 6 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.59.CAPRICOR THERAPEUTICS - BELIEVES CURRENT FINANCIAL RESOURCES SHOULD BE SUFFICIENT TO FUND OPERATIONS AND MEET FINANCIAL OBLIGATIONS INTO Q1 OF 2020.AS OF JUNE 30, 2019, COMPANY'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED APPROXIMATELY $5.9 MILLION.  Full Article

Capricor Therapeutics Will Continue Ongoing Discussions With FDA About DMD Program
Monday, 15 Jul 2019 

July 15 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM ITS INTERIM ANALYSIS IN THE HOPE-2 TRIAL TO TREAT PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY.CAPRICOR THERAPEUTICS - INTERIM ANALYSIS SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENTS IN PERFORMANCE OF UPPER LIMB, GRIP STRENGTH, INSPIRATORY FLOW RESERVE IN STUDY.CAPRICOR THERAPEUTICS INC - WILL CONTINUE ITS ONGOING DISCUSSIONS WITH FDA ABOUT DMD PROGRAM AND FUTURE PLANS.  Full Article

Capricor Therapeutics Inc says Board Of Directors Of Capricor Acted To Set Reverse Stock Split Ratio At 110
Wednesday, 5 Jun 2019 

June 4 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS INC - BOARD OF DIRECTORS OF CAPRICOR ACTED TO SET REVERSE STOCK SPLIT RATIO AT 1:10.CAPRICOR THERAPEUTICS-REVERSE STOCK SPLIT WILL REDUCE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING FROM ABOUT 34.7 MILLION SHARES TO ABOUT 3.5 MILLION SHARES.CAPRICOR THERAPEUTICS INC - COMMON STOCK IS EXPECTED TO BEGIN TRADING ON A REVERSE STOCK SPLIT-ADJUSTED BASIS ON NASDAQ CAPITAL MARKET ON JUNE 5, 2019.  Full Article

Capricor Therapeutics Reports Q1 Loss Per Share $0.08
Tuesday, 14 May 2019 

May 13 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.08.ON TRACK TO REPORT INTERIM DATA FROM HOPE-2 CLINICAL TRIAL IN EARLY Q3.BELIEVES CURRENT FINANCIAL RESOURCES SUFFICIENT TO FUND OPERATIONS INTO Q4 OF 2019.  Full Article

Capricor Therapeutics Q4 Loss Per Share $0.11
Friday, 29 Mar 2019 

March 28 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.11.PLAN TO REPORT INTERIM DATA FROM HOPE-2 CLINICAL TRIAL IN EARLY Q3.CAPRICOR THERAPEUTICS - BELIEVES CURRENT FINANCIAL RESOURCES SHOULD BE SUFFICIENT TO FUND OPERATIONS, MEET FINANCIAL OBLIGATIONS INTO Q4 2019.  Full Article

Capricor Resumes Dosing Of Enrolled Patients In Hope-2 Clinical Trial For Duchenne Muscular Dystrophy
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR RESUMES DOSING OF ENROLLED PATIENTS IN HOPE-2 CLINICAL TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY.CAPRICOR THERAPEUTICS - TO REDUCE EXPENSES & BETTER ALIGN RESOURCES, PERSONNEL ON CORE LEAD PROGRAMS, CO HAS REDUCED STAFF BY 21 FULL-TIME EMPLOYEES.CAPRICOR THERAPEUTICS - REDUCTION IN OPERATING EXPENSES IS EXPECTED TO EXTEND CO'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES INTO LATE 2019.CAPRICOR THERAPEUTICS - ADDITIONALLY, CO IS EXPLORING STRATEGIC ALTERNATIVES, WITH RESPECT TO ONE OR MORE OF ITS PRODUCT CANDIDATES.CAPRICOR THERAPEUTICS - U.S. FDA AND DATA AND SAFETY MONITORING BOARD HAVE GRANTED PERMISSION TO RESUME ENROLLMENT IN HOPE-2 STUDY.CAPRICOR THERAPEUTICS-ENROLLMENT OF NEW PATIENTS IN HOPE-2 TRIAL TO DEPEND ON VARIOUS FACTORS BUT TO NOT COMMENCE UNTIL ADDITIONAL FUNDING IS SECURED.  Full Article

Capricor Therapeutics Inc Files For Mixed Shelf Of Upto $75 Mln
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $75 MILLION - SEC FILING.  Full Article

Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing
Saturday, 23 Dec 2017 

Dec 22 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS INC SAYS HAS APPOINTED ANTHONY BERGMANN AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2018 - SEC FILING.CAPRICOR THERAPEUTICS INC - ON DEC 20, LELAND GERSHELL GAVE NOTICE OF HIS RESIGNATION AS CHIEF FINANCIAL OFFICER OF COMPANY, EFFECTIVE JANUARY 1, 2018.  Full Article

Capricor & California Institute For Regenerative Medicine​ Entered Into Amendment 3 To CIRM Notice Loan Award
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR SAYS ‍ON DEC 11, CO, CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE​ ENTERED INTO AMENDMENT NO. 3 TO CIRM NOTICE OF LOAN AWARD - SEC FILING.CAPRICOR SAYS PURSUANT TO AMENDMENT, TOTAL LOAN BALANCE UNDER LOAN AWARD FORGIVEN BY CIRM, TERMINATING UNIT, CO'S OBLIGATION TO REPAY LOAN BALANCE​.CAPRICOR - ‍DECISION TO TERMINATE LOAN AWARD AND FORGIVE LOAN BALANCE WAS DUE TO ABANDONMENT OF ALLSTAR PROJECT AT END OF PROJECT PERIOD​.  Full Article

Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002.CAPRICOR THERAPEUTICS INC - POTENTIAL REGISTRATION TRIAL IN DUCHENNE MUSCULAR DYSTROPHY ON TRACK TO INITIATE IN Q1 OF 2018.CAPRICOR THERAPEUTICS-PLANS TO APPLY FOR REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR CAP-1002 BASED ON UPDATED GUIDANCE RECENTLY ISSUED BY FDA.  Full Article